C. Lamb

1011 poster DOES MARKER-BASED PROSTATE RADIOTHERAPY CAUSE WORSE ACUTE TOXICITY?

lymph nodes. Hormone therapy included ablation (surgical or pharmacological) or maximal androgen blockade (MAB) but for group when was combined with RT was started at least 2 months before RT and continued concurrently and then administered in adjuvant fashion for minimum duration of 24 months. Results: The 5-year overall survival (OS) was 75% in combined (HT + RT) arm and 59% in HT, respectively (p= 0.03). Median overall survival time was 62.2 months in HT alone arm and 70.8 months in combined treatment. Actuarial 5-year cancer specific survival (CSS) was 83% in (HT + RT) group and 70% in HT group (p= 0.01). Actuarial 5-year distant metastases-free survival in (HT + RT) was 79% and 54% in HT alone group (p= 0.007). Median biochemical progression-free survival for HT group was 34 months and 59.4 months in HT + RT group (p= 0.000). Conclusions: Combined treatment with hormone therapy and radiotherapy shows benefit when compared with hormone therapy alone in terms of overall survival, cancer specific survival, distant metastases-free survival and biochemical progression-free survival. Acute and late treatment toxicity level in combined arm was low and in addition had now adverse effect on quality of life measures when compared to hormone therapy alone.